Transfusion requirements and effects in patients with thalassaemia major

Paolo Rebulla, Berndette Modell

Research output: Contribution to journalArticle

Abstract

Analysis of data available in 1985 on 3468 Italian and Greek patients registered in Cooleycare, an international cooperative programme of quality assessment of treatment delivery in thalassaemia, gave the following picture of treatment requirements and effects. The proportion of patients undergoing splenectomy has progressively decreased, and age at splenectomy has increased with time over the past 20 years. Age at first transfusion exceeds 4 years in a small but important group of patients, which indicates that a milder form of thalassaemia exists in this group. Children receiving modern treatment remain of near-normal stature until age 11 but later tend to be stunted. The mean blood requirement is 35% higher in non-splenectomised than in splenectomised patients. Differences in transfusion interval of 2 to 4 weeks have no measurable effect on blood requirement. Mean blood requirement rises gradually with mean haemoglobin concentration, possibly in a non-linear fashion. The prevalence of red cell alloimmunisation rises with delay in start on transfusion. Transfusion reactions were reported in 1% of transfusions (90% of which were leucocyte-depleted), from 17% of patients.

Original languageEnglish
Pages (from-to)277-280
Number of pages4
JournalLancet
Volume337
Issue number8736
DOIs
Publication statusPublished - Feb 2 1991

Fingerprint

beta-Thalassemia
Thalassemia
Splenectomy
Hemoglobins
Leukocytes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Transfusion requirements and effects in patients with thalassaemia major. / Rebulla, Paolo; Modell, Berndette.

In: Lancet, Vol. 337, No. 8736, 02.02.1991, p. 277-280.

Research output: Contribution to journalArticle

Rebulla, Paolo ; Modell, Berndette. / Transfusion requirements and effects in patients with thalassaemia major. In: Lancet. 1991 ; Vol. 337, No. 8736. pp. 277-280.
@article{f9c3dfc939954a209443f5260bdae1a9,
title = "Transfusion requirements and effects in patients with thalassaemia major",
abstract = "Analysis of data available in 1985 on 3468 Italian and Greek patients registered in Cooleycare, an international cooperative programme of quality assessment of treatment delivery in thalassaemia, gave the following picture of treatment requirements and effects. The proportion of patients undergoing splenectomy has progressively decreased, and age at splenectomy has increased with time over the past 20 years. Age at first transfusion exceeds 4 years in a small but important group of patients, which indicates that a milder form of thalassaemia exists in this group. Children receiving modern treatment remain of near-normal stature until age 11 but later tend to be stunted. The mean blood requirement is 35{\%} higher in non-splenectomised than in splenectomised patients. Differences in transfusion interval of 2 to 4 weeks have no measurable effect on blood requirement. Mean blood requirement rises gradually with mean haemoglobin concentration, possibly in a non-linear fashion. The prevalence of red cell alloimmunisation rises with delay in start on transfusion. Transfusion reactions were reported in 1{\%} of transfusions (90{\%} of which were leucocyte-depleted), from 17{\%} of patients.",
author = "Paolo Rebulla and Berndette Modell",
year = "1991",
month = "2",
day = "2",
doi = "10.1016/0140-6736(91)90881-O",
language = "English",
volume = "337",
pages = "277--280",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "8736",

}

TY - JOUR

T1 - Transfusion requirements and effects in patients with thalassaemia major

AU - Rebulla, Paolo

AU - Modell, Berndette

PY - 1991/2/2

Y1 - 1991/2/2

N2 - Analysis of data available in 1985 on 3468 Italian and Greek patients registered in Cooleycare, an international cooperative programme of quality assessment of treatment delivery in thalassaemia, gave the following picture of treatment requirements and effects. The proportion of patients undergoing splenectomy has progressively decreased, and age at splenectomy has increased with time over the past 20 years. Age at first transfusion exceeds 4 years in a small but important group of patients, which indicates that a milder form of thalassaemia exists in this group. Children receiving modern treatment remain of near-normal stature until age 11 but later tend to be stunted. The mean blood requirement is 35% higher in non-splenectomised than in splenectomised patients. Differences in transfusion interval of 2 to 4 weeks have no measurable effect on blood requirement. Mean blood requirement rises gradually with mean haemoglobin concentration, possibly in a non-linear fashion. The prevalence of red cell alloimmunisation rises with delay in start on transfusion. Transfusion reactions were reported in 1% of transfusions (90% of which were leucocyte-depleted), from 17% of patients.

AB - Analysis of data available in 1985 on 3468 Italian and Greek patients registered in Cooleycare, an international cooperative programme of quality assessment of treatment delivery in thalassaemia, gave the following picture of treatment requirements and effects. The proportion of patients undergoing splenectomy has progressively decreased, and age at splenectomy has increased with time over the past 20 years. Age at first transfusion exceeds 4 years in a small but important group of patients, which indicates that a milder form of thalassaemia exists in this group. Children receiving modern treatment remain of near-normal stature until age 11 but later tend to be stunted. The mean blood requirement is 35% higher in non-splenectomised than in splenectomised patients. Differences in transfusion interval of 2 to 4 weeks have no measurable effect on blood requirement. Mean blood requirement rises gradually with mean haemoglobin concentration, possibly in a non-linear fashion. The prevalence of red cell alloimmunisation rises with delay in start on transfusion. Transfusion reactions were reported in 1% of transfusions (90% of which were leucocyte-depleted), from 17% of patients.

UR - http://www.scopus.com/inward/record.url?scp=0025970809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025970809&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)90881-O

DO - 10.1016/0140-6736(91)90881-O

M3 - Article

C2 - 1671122

AN - SCOPUS:0025970809

VL - 337

SP - 277

EP - 280

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8736

ER -